<DOC>
	<DOC>NCT00245388</DOC>
	<brief_summary>This is a randomized, double-blind, dose-ranging, placebo-controlled trial to determine the lipid-lowering efficacy and safety of BMS-298585 (muraglitazar) alone in combination with pravastatin in subjects with mixed dyslipidemia.</brief_summary>
	<brief_title>Efficacy and Safety of BMS-298585 Alone or in Combination With Pravastatin in Subjects With Mixed Dyslipidemia</brief_title>
	<detailed_description />
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Pravastatin</mesh_term>
	<criteria>Nondiabetics Serum TG &gt;150 mg/dL and &lt; or = 600 mg/dL Serum LDLC &gt;130 mg/dL Type 1 or type 2 diabetics Fasting plasma glucose &gt;126 mg/dL Treatment with lipidlowering drugs, unless they can be withdrawn within the following time frame prior to the first qualifying lipid determination (Week 2): Niacin or bileacid binding agents and HMG CoA reductase inhibitors: 8 weeks Fibrates: 8 weeks Probucol: 1 year History of active liver disease and/or history of thiazolidinedionerelated (troglitazone, rosiglitazone, or pioglitazone) liver abnormalities, hepatic dysfunction, or jaundice</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Mixed Dyslipidemia</keyword>
</DOC>